The U.S. Food and Drug Administration (FDA) has officially approved Yeztugo, a new injectable medication developed by Gilead Sciences to prevent HIV. Announced on Wednesday, this is the first HIV prevention shot that only needs to be administered twice a year.
Designed for adults and adolescents at risk of acquiring HIV through sex, Yeztugo represents a major shift in the way prevention can be managed. Gilead’s CEO, Daniel O’Day, described the approval as a “historic day” in the ongoing battle against HIV.
Clinical trials showed impressive results. Yeztugo was found to be nearly 100% effective in preventing sexually transmitted HIV, making it even more reliable than daily oral medications like Truvada. For people who find it hard to stick to daily pill routines, this twice-yearly option offers a game-changing alternative.
Before starting the treatment, patients must test negative for HIV-1 to ensure safety and effectiveness. As with most injectables, some people may experience mild side effects, including pain or swelling at the injection site, headaches, or nausea.
Yeztugo’s approval is being seen as a breakthrough for HIV prevention, offering a more convenient, long-acting solution that could significantly expand access and adherence across communities most at risk.
By Risper Akinyi
